Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Davine Hofste op Bruinink; Stefania Oliva; Lucie Rihova; Alexander Schmitz; Milena Gilestro; Jeroen Te Marvelde; Romana Kralova; Helle Høholt; Annemiek Broijl; Hans Erik Johnsen; Roman Hajek; Mario Boccadoro; Pieter Sonneveld; Paola Omedè; Vincent H J Van der Velden

doi:10.3324/haematol.2020.267831

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831.

Authors

Affiliations

¹ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . d.hofsteopbruinink@erasmusmc.nl.
² Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
³ Department of Hematology, University Hospital Brno, Brno, Czech Republic.
⁴ Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
⁵ Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
⁶ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
⁷ Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic.
⁸ Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . v.h.j.vandervelden@erasmusmc.nl.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Feasibility Studies
Flow Cytometry
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / therapy
Neoplasm, Residual
Reference Standards

Grants and funding

Funding: this work was supported by grants from the European Myeloma Network and the Ministry of Health of the Czech Republic (grant number 17-30089A).